fPSA、TPSA及其比值在前列腺癌鉴别诊断中的应用评价

Clinical evaluation of TPSA,fPSA and the ratio of fPSA/TPSA in differential diagnosis of prostate cancer(PCa)

目的观察血清总前列腺特异性抗原（TPSA）、游离前列腺特异性抗原（fPSA）及fPSA／TPSA比值在前列腺癌症鉴别诊断中的价值。方法采用微粒子酶免疫技术，测量BPH和前列腺癌症患者的血清TPSA、fPSA，并计算f／T比值。结果前列腺癌（PCa）组、前列腺增生（BPH）组与正常对照组差异有非常显著性（P〈0．01）；在诊断灰区内（TPSA4．0～20．0μg／L）PCa组与BPH组TPSA、fPSA差异无显著性（P〉0．05），而f／T比值有明显差异（P〈0．01）。结论运用fPSA／TPSA比值，结合TPSA含量，可提高PCa与BPH鉴别诊断的特异性，对PCa的鉴别诊断疗效观察及高危人群的筛查等具有重要意义。

Objective To study the value of TPSA,fPSA and the ratio of fPSA/TPSA in differential diagnosis of prostate cancer（PCa）. Methods Three groups：healthy males,males with BPH and protstate cancer patients were included in this study, fPSA and TPSA were measured with Microparticle Enzyme lmmunoassay （MEIA） technology. The fit ratio was calculated based on the results. Results TPSA in both healthy group and radical prostatectomy（P〈0.01） ;TPSA in both of healthy group and prostate cancer （P〈0.01）. TPSA in the 4.0-20.0μg/L,TPSA in both radical prostatectomy and prostate cancer（P〉0.05）;fPSA/TPSA（P〈0.01）. Conclusion Improvement of the differential diagnosis between PCa and BPH can be achieved by using the ratio of fPSA/TPSA combined with the serum TPSA. It is important for the observation of the differential diagnosis and the therapeutic effects of PCa and the screening of the high risk persons.